Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication

World Journal of Gastroenterology

Volumn 16, Issue 34, 2010, Pages 4357-4362

  Gao, Xiao Zhong ^a   Qiao, Xiu Li ^a   Song, Wen Chong ^a   Wang, Xiao Feng ^a   Liu, Feng ^a  

^a WEIHAI MUNICIPAL HOSPITAL   (China)

Author keywords

Bismuth pectin quadruple therapy; Eradication rate; Helicobacter pylori; Sequential therapy; Triple therapy

Indexed keywords

AMOXICILLIN; BISMUTH; CARBON 13; CLARITHROMYCIN; LEVOFLOXACIN; OMEPRAZOLE; PECTIN; RABEPRAZOLE; TINIDAZOLE; UREASE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GASTROSCOPY; GLOSSITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NAUSEA AND VOMITING; OPEN STUDY; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SCAR FORMATION; TREATMENT DURATION; ULCER; UREA BREATH TEST; VOMITING;

EID: 77957597261     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i34.4357     Document Type: Article

References (36)

1. Huang JQ, Hunt RH. The evolving epidemiology of Helicobacter pylori infection and gastric cancer. Can J Gastroenterol 2003; 17 Suppl B: 18B-20B
2. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
3. Vaira U, Gatta L, Ricci C, D'Anna L, Iglioli MM. Helicobacter pylori: diseases, tests and treatment. Dig Liver Dis 2001; 33: 788-794
4. Nardone G. Risk factors for cancer development in Helicobacter pylori gastritis. Dig Liver Dis 2000; 32 Suppl 3: S190-S192
5. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621-2626
6. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73
7. Sharma VK, Howden CW. A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection. J Clin Gastroenterol 2004; 38: 326-331
8. Realdi G, Dore MP, Piana A, Atzei A, Carta M, Cugia L, Manca A, Are BM, Massarelli G, Mura I, Maida A, Graham DY. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999; 4: 106-112
9. De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Berloco P, Russo F, Barone M, Di Leo A, Minenna MF, Stoppino V, Morini S, Panella C, Francavilla A, Ierardi E. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004; 19: 407-414
10. Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Boscarelli G, Piscitelli D, Amoruso A, Di Leo A, Miniello VL, Francavilla A, Cavallo L, Ierardi E. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005; 129: 1414-1419
11. Logan RP, Gummett PA, Hegarty BT, Walker MM, Baron JH, Misiewicz JJ. Clarithromycin and omeprazole for Helicobacter pylori. Lancet 1992; 340: 239
12. Talamini G, Zamboni G, Cavallini G. Antral mucosal Helicobacter pylori infection density as a risk factor of duodenal ulcer. Digestion 1997; 58: 211-217
13. Janssen MJ, Van Oijen AH, Verbeek AL, Jansen JB, De Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther 2001; 15: 613-624
14. Hunt R, Fallone C, Veldhuyzan van Zanten S, Sherman P, Smaill F, Flook N, Thomson A. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol 2004; 18: 547-554
15. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocellá L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002; 16: 1269-1275
16. Shirin H, Birkenfeld S, Shevah O, Levine A, Epstein J, Boaz M, Niv Y, Avni Y. Application of Maastricht 2-2000 guidelines for the management of Helicobacter pylori among specialists and primary care physicians in israel: are we missing the malignant potential of Helicobacter pylori? J Clin Gastroenterol 2004; 38: 322-325
17. Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, Faleo D, Attili AF. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and retreatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13: 163-168
18. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 383-388
19. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-496
20. Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M. Safety and efficacy of 7-day rabeprazole- and omeprazolebased triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacol Ther 2003; 17: 1065-1074
21. Kashimura H, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, Nakahara A, Mutoh H, Tanaka N. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 483-487
22. Wong BC, Chang FY, Abid S, Abbas Z, Lin BR, Van Rensburg C, Chen PC, Schneider H, Simjee AE, Hamid SS, Seebaran A, Zhang J, Destefano M, Lam SK. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 2000; 14: 1529-1535
23. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, Levine JG. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000; 95: 3393-3398
24. Vakil N, Cutler A. Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Am J Gastroenterol 1999; 94: 1197-1199
25. Veldhuyzen Van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metro-nidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1381-1387
26. Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004; 10: 1656-1658
27. Pilotto A, Leandro G, Franceschi M, Rassu M, Bozzola L, Furlan F, Di Mario F, Valerio G. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999; 13: 667-673
28. Mégraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998; 54: 207-216
29. Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C, Tomaselli G, Attili AF. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-718
30. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, Cavina M, Ierardi E, Morini S, Vaira D. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005; 21: 1419-1424
31. Sánchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Titó L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008; 103: 2220-2223
32. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-1357
33. Queiroz DM, Dani R, Silva LD, Santos A, Moreira LS, Rocha GA, Corrêa PR, Reis LF, Nogueira AM, Alvares Cabral MM, Esteves AM, Tanure J. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002; 35: 315-320
34. Helicobacter pylori Group of Chinese Society of Gastroenterology/National Helicobacter pylori scientific research cooperative Group. Prevalence of Helicobacter pylori resistance to antibiotics and its influence on the treatment outcome in China: A multicenter clinical study. Weichangbingxue 2007; 12: 525-530
35. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G, Cea U, Pace A, Zotti M, Morini S, Panella C, Ierardi E. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007; 59: 783-785
36. Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J Med Microbiol 2000; 49: 415-418